Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DCTH vs BBNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–3 Matrix Metrics)
DCTH Overall Winner
6-Pillar Tally: DCTH 6 – 0 BBNX
Matrix Metrics: DCTH 6 – 3 BBNX
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $15.60 (N/M Forward P/E, -72.8% operating margin).
- Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -72.8% operating margin) and revenue trajectory (+70.7% vs. +30.3% YoY).
- Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DCTH vs BBNX
DCTH
Head-to-Head Winner
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
BBNX
Beta Bionics, Inc. Common Stock
$15.60
-4.99% 1D
Market Cap
$897.6M
TTM Revenue
$127M
Forward P/E
N/M
Beta / 30D Vol
1.83β · 108% Vol
Unified Composite Score
52.1
HOLD
Tech 51.0
Fund 59.0
Flow 57.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 BBNX)
1. Valuation Multiples
DCTH
Forward P/E
N/M
N/M
Trailing P/E
133.6x
N/M
PEG Ratio
1.60x
N/M
EV / Revenue
6.3x
6.5x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+70.7%
+30.3%
Earnings Growth (YoY)
+750.0%
+0.0%
TTM Revenue (USD)
$110M
$127M
Market Cap
$743.8M
$897.6M
3. Profitability & Quality
DCTH
Gross Margin
87.6%
58.6%
Operating Margin
5.2%
-72.8%
Net Profit Margin
6.0%
-65.3%
Return on Equity (ROE)
5.4%
-23.9%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
$20M
-$66M
Cash Flow Margin
18.3%
-51.8%
Net Cash / Leverage
$53M Net Cash
$75M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
BREAKOUT
CONSOLIDATION
Current IV / %ile
109.3% (43rd %ile)
217.1% (54th %ile)
Put/Call OI Skew
0.11x (Call-Skewed)
0.02x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
82.4% of Rev ($91M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DCTH (6) vs BBNX (3)| Institutional Metric | DCTH | BBNX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $743.8M | $897.6M | BBNX | |
| Trailing P/E Ratio | 133.6x | N/M | DCTH | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +70.7% | +30.3% | DCTH | |
| Operating Margin (TTM) | 5.2% | -72.8% | DCTH | |
| Net Profit Margin | 6.0% | -65.3% | DCTH | |
| Return on Equity (ROE) | 5.4% | -23.9% | DCTH | |
| 52-Week Range Position | 80% ($8–$23) | 28% ($9–$33) | DCTH | |
| Beta / 30D Volatility | 1.63β · 131% Vol | 1.83β · 108% Vol | BBNX | |
| Unified Institutional Score | 35.9 / 100 (SELL) | 52.1 / 100 (HOLD) | BBNX | |
| Trailing 12M Revenue (USD) | $110M | $127M | Scale | |
| Gross Profit Margin (TTM) | 87.6% | 58.6% | Quality | |
| PEG Ratio & EV / Revenue | 1.60x PEG · 6.3x EV/Rev | N/M PEG · 6.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $20M ($53M Net Cash) | -$66M ($75M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +44.36 pp
3M Horizon
DCTH +34.71 pp
6M Horizon
DCTH +11.5 pp
1Y Horizon
DCTH +169.12 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | BBNX Revenue | DCTH Op. Margin | BBNX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2013 | $0M | N/A | -4179.6% | N/A | DCTH |
| FY2014 | $0M | N/A | -1805.8% | N/A | DCTH |
| FY2015 | $0M | N/A | -870.6% | N/A | DCTH |
| FY2021 | $0M | N/A | -690.0% | N/A | DCTH |
| FY2022 | $0M | N/A | -1245.1% | N/A | DCTH |
| FY2023 | $0M | $10M | -1849.0% | -298.9% | BBNX |
| FY2024 | $40M | $70M | -33.4% | -69.5% | DCTH |
| FY2025 | $90M | $100M | 0.8% | -71.5% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BBNX
CONSOLIDATION
Current IV
217.1%
IV Percentile
54th %ile
Put/Call OI Skew
0.02x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact BBNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
BBNX Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DCTH vs BBNX Key Questions & Quantitative Answers
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $15.60 (N/M Forward P/E, -72.8% operating margin). Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -72.8% operating margin) and revenue trajectory (+70.7% vs. +30.3% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with BBNX at +30.3% YoY revenue growth and +0.0% YoY earnings growth on $127M TTM revenue (58.6% gross margin, -72.8% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), DCTH cumulative revenue shifted +125.0% while BBNX shifted +900.0%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBNX.
DCTH screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas BBNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.5x EV/Revenue (-51.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus BBNX (-23.9% ROE) capital efficiency.
In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, BBNX carries 217.1% implied volatility (54th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.83β · 108% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BBNX vs DCTH · Reverse Pair
DCTH vs CRMD
· Sector Peer
BBNX vs KMTS
· Sector Peer
BBNX vs CBLL
· Sector Peer
BBNX vs MAZE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma